PT804584E - Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico - Google Patents

Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico

Info

Publication number
PT804584E
PT804584E PT95936537T PT95936537T PT804584E PT 804584 E PT804584 E PT 804584E PT 95936537 T PT95936537 T PT 95936537T PT 95936537 T PT95936537 T PT 95936537T PT 804584 E PT804584 E PT 804584E
Authority
PT
Portugal
Prior art keywords
sequences
therapeutic
genotype
hepatitis
proprietary
Prior art date
Application number
PT95936537T
Other languages
English (en)
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26137782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT804584(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of PT804584E publication Critical patent/PT804584E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT95936537T 1994-10-21 1995-10-23 Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico PT804584E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94870166 1994-10-21
EP95870076 1995-06-28

Publications (1)

Publication Number Publication Date
PT804584E true PT804584E (pt) 2002-11-29

Family

ID=26137782

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95936537T PT804584E (pt) 1994-10-21 1995-10-23 Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico

Country Status (12)

Country Link
US (2) US7129337B1 (pt)
EP (2) EP0804584B2 (pt)
JP (2) JPH10507643A (pt)
AT (1) ATE218617T1 (pt)
AU (1) AU702436B2 (pt)
BR (1) BR9509421A (pt)
CA (1) CA2201703A1 (pt)
DE (1) DE69526973T3 (pt)
DK (1) DK0804584T3 (pt)
ES (1) ES2176342T5 (pt)
PT (1) PT804584E (pt)
WO (1) WO1996013590A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620075D0 (en) * 1996-09-26 1996-11-13 Dynal As Method
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
AU751362B2 (en) 1998-04-17 2002-08-15 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
WO1999055385A2 (de) * 1998-04-28 1999-11-04 Wolfgang Bergter Radioimmunpharmaka zur therapie der hepatitis c
DK1090033T4 (da) * 1998-06-24 2008-03-31 Innogenetics Nv Partikler af HCV-kappeproteiner: Anvendelse til vaccination
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
ATE375804T1 (de) * 2000-08-17 2007-11-15 Tripep Ab Ribavirin-enthaltende vakzine
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
GB0126782D0 (en) * 2001-11-07 2002-01-02 Medical Res Council Assay
US8124747B2 (en) * 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
CN1977050B (zh) * 2004-01-07 2012-09-05 第三次浪潮技术公司 丙型肝炎病毒基因型的确定
RU2267496C2 (ru) * 2004-01-15 2006-01-10 Сергей Иванович Черныш Противоопухолевые и антивирусные пептиды
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20070072211A1 (en) 2005-06-30 2007-03-29 Roche Molecular Systems, Inc. Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids
PT2361638E (pt) 2005-12-12 2014-04-17 Ac Immune Sa Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
TW201815827A (zh) 2006-07-14 2018-05-01 瑞士商Ａｃ免疫公司 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法
KR101500017B1 (ko) * 2006-08-25 2015-03-09 더 맥파레인 버넷 인스티튜트 포 메디칼 리서치 앤드 퍼블릭 헬스 리미티드 재조합 ｈｃｖ ｅ2 당단백질
EP2463389A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
KR20160017126A (ko) 2007-06-12 2016-02-15 에이씨 이뮨 에스.에이. 모노클로널 항 베타 아밀로이드 항체
PE20090766A1 (es) 2007-06-12 2009-07-09 Ac Immune Sa Anticuerpo igg1 humanizado
US20100227314A1 (en) * 2007-08-09 2010-09-09 Dmitry Alexandrovich Gryadunov Method of identification of genotype and subtype of hepatitis c virus on a biological microchip
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
MX337548B (es) 2010-04-16 2016-03-10 Ac Immune Sa Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide.
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
MX354662B (es) 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
SI2859017T1 (sl) 2012-06-08 2019-05-31 Sutro Biopharma, Inc. Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CN102766701B (zh) * 2012-07-04 2016-05-04 福州泰普生物科学有限公司 丙型肝炎病毒基因分型的试剂盒及方法
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
WO2014183109A1 (en) * 2013-05-10 2014-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for simultaneous detection of hcv antigen/antibody
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015032932A1 (en) 2013-09-05 2015-03-12 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
EP3472197A1 (en) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
WO1991004262A1 (en) 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
DK298190A (da) 1989-12-18 1991-06-19 Wellcome Found Viralt middel
CA2045326A1 (en) 1990-06-25 1991-12-26 Hiroto Okayama Non-a, non-b, hepatitis virus particles
ATE252154T1 (de) 1991-05-08 2003-11-15 Chiron Corp Genomische hcv-sequenzen für diagnostik und therapie
RO117329B1 (ro) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polipeptide care contin o secventa a virusului hepatitei c
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
JPH06511149A (ja) 1991-09-13 1994-12-15 カイロン　コーポレイション 免疫反応性ｃ型肝炎ウイルスのポリペプチド組成物
JP3688290B2 (ja) 1991-11-21 2005-08-24 コモン サーヴィシス エージェンシー Ｃ型肝炎ウイルス検査
ATE373093T1 (de) * 1993-04-27 2007-09-15 Innogenetics Nv Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
JPH06319563A (ja) * 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines

Also Published As

Publication number Publication date
ES2176342T3 (es) 2002-12-01
WO1996013590A3 (en) 1996-08-15
JP2005118044A (ja) 2005-05-12
EP1076092A2 (en) 2001-02-14
DE69526973D1 (de) 2002-07-11
US20020183508A1 (en) 2002-12-05
EP0804584B2 (en) 2008-07-09
CA2201703A1 (en) 1996-05-09
BR9509421A (pt) 1997-09-30
US6974864B2 (en) 2005-12-13
US7129337B1 (en) 2006-10-31
AU702436B2 (en) 1999-02-18
ES2176342T5 (es) 2010-02-09
DE69526973T3 (de) 2010-01-07
ATE218617T1 (de) 2002-06-15
AU3844095A (en) 1996-05-23
DE69526973T2 (de) 2003-01-02
EP0804584B1 (en) 2002-06-05
JPH10507643A (ja) 1998-07-28
DK0804584T3 (da) 2002-09-23
WO1996013590A2 (en) 1996-05-09
EP0804584A1 (en) 1997-11-05
EP1076092A3 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
PT804584E (pt) Sequencias de virus da hepatite c genotipo 7 e sua utilizacao como agentes profilacticos terapeuticos e de diagnostico
BR9405334A (pt) Novas sequências de genótipos de vírus da hepatite c e seu uso como agentes terapêuticos e diagnóstico
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
MC2188A1 (fr) Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
NO923821L (no) Diagnostiske midler
DE69015261D1 (de) Verfahren zum Nachweis des humanen Papillomvirus.
NO20000514L (no) Oligonukleotidprimere for effektiv multipleksdeteksjon av Hepatitt C-virus (HCV) og human immunosviktvirus (HIV) og metoder for anvendelse derav
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
ES2141094T3 (es) Deteccion directa del arn del virus de la hepatitis c.
DE69011122D1 (de) Rubella-e1 und c peptide.
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
DE68926245D1 (de) Nachweis der basismembrankomponenten, diagnose von krebs und sonstigen krankheiten
ATE482974T1 (de) Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
AU756661C (en) Novel (poly)peptides which represent the epitopes of the human herpes virus type 8
EP0391330A3 (de) Verfahren zur Bestimmung von Antikörpern gegen Erreger von Infektionskrankheiten in Körperflüssigkeiten, Mittel dazu und ihre Verwendung in diesem Verfahren
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same
DE3788424D1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).
RU98113331A (ru) Способ диагностики бактериальной аллергии
ATE98379T1 (de) Testverfahren des menschlichen b-lymphotropen virus (hblv).